Resources
217 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 11/24/2021 (updated 3/26/2024)
This webinar will provide participants with an understanding of the role of the medical examiners and coroners in the surveillance of drug overdose deaths, as well as the current efforts to strengthen the death investigation system. The webinar will also cover an overview of the overdose fatality review process and tools available for implementation.
Posted 11/30/2021 (updated 3/26/2024)
Peer providers are viable, evidence based, stand alone or additions to comprehensive teams that approach struggle interventions. Peer providers can be appropriate for any environment that have people with challenges ranging from substance use, gun violence, domestic violence to mental health experiences.
Learning Objectives:
What are the certifications that a peer provider can receive? You will walk away knowing various ways peers can show up in the workplace.
What additional training do peer providers need? Information on what trainings would be helpful for peers to be able to support others well will be provided.
How do we find, support and retain peer providers in the work place? Knowing where to recruit peers, how to keep the workplace well for peer will be knowledge you will leave with.
Presenter: Tanya Kraege
Posted 1/19/2022 (updated 3/26/2024)
With the worst opioid overdose death crisis in the United States history, urgent new approaches to assist people who use drugs onto medication for opioid use disorder are necessary. In this commentary, addiction medicine clinicians and drug user union representatives align to argue that conventional ways of buprenorphine initiation that require periods of withdrawal must be augmented with additional novel approaches to initiation.
Posted 2/9/2022 (updated 3/26/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. These measures are pending OMB clearance and are subject to revision. This page contains the RCORP data collection resources for the Psychostimulant Support grantees only.
These documents will be updated as new guidance or data sources are identified. We encourage you to bookmark this page so you have the latest version available. Please send any measure-related questions to your HRSA Project Officer or email: rcorp-eval@jbsinternational.com.
Posted 7/31/2023 (updated 3/26/2024)
This presentation will cover health equity regarding rural American Indian and Alaska Native (AI/AN) communities' prevention and treatment efforts to address substance use disorder (SUD), including the need for contingency management for stimulants.
Posted 8/8/2023 (updated 3/26/2024)
This webinar is an invaluable opportunity for health care professionals, policymakers, researchers, and anyone else interested in mental health and substance use interventions to learn about the latest research and innovative approaches in the field.
Posted 8/22/2023 (updated 3/26/2024)
Posted 2/16/2022 (updated 3/26/2024)
Nearly 92,000 Americans died of drug overdoses in 2020, marking a 30% increase from the year before, a 75% increase over five years and by far the highest annual total on record, according to the Centers for Disease Control and Prevention (CDC). Preliminary figures suggest that the 2021 death toll from overdoses may be even higher.
While overdose death rates have increased in every major demographic group in recent years, no group has seen a bigger increase than Black men. As a result, Black men have overtaken White men and are now on par with American Indian or Alaska Native men as the demographic groups most likely to die from overdoses.
Posted 2/16/2022 (updated 3/26/2024)
In the United States, combined stimulant/opioid overdose mortality has risen dramatically over the last decade. These increases may particularly affect non-Hispanic Black and Hispanic populations. We used death certificate data from the US National Center for Health Statistics (2007–2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander).
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).